Fears Nachawati Trial Lawyers Challenge Bayer AG’s Latest Bid to Reduce Weed Killer Liabilities

Proposal would have chilling effect on pursuit of justice for more than 50,000 cancer victims nationwide

Bayer AG (OTCMKTS:BAYRY)

There are more than 50,000 cases nationwide that remain unresolved and would remain so if this company had its way.”

— Majed Nachawati

DALLAS, TEXAS, UNITED STATES, July 30, 2021 /EINPresswire.com/ — The latest legal maneuver designed to help Bayer AG (OTCMKTS: BAYRY) circumvent its legal responsibility to cancer victims exposed to the weed killer Roundup has drawn a swift rebuke from the trial lawyers of the Dallas-based Fears Nachawati Law Firm, who represent thousands of individuals who have developed non-Hodgkin’s lymphoma after exposure to Roundup.

U.S. District Judge Vince Chhabria, tasked with overseeing the entire Roundup multidistrict litigation (MDL), rejected a proposed class-action settlement in May that would have limited the ability of cancer victims exposed to Roundup to pursue lawsuits.

Despite Judge Chhabria’s ruling, Bayer AG again sought to limit its potential liabilities by entering into another purported class-action settlement, this time in federal district court in Delaware.

This week, in order to protect the victims of Roundup, Fears Nachawati filed a brief in support of the transfer of the Delaware class-action litigation into the MDL and asked for all future class-certification and settlement decisions to be made by the MDL judge.

“Judge Chhabria has consistently provided thoughtful leadership and direction throughout the course of this litigation. His rulings, including his recent denial of Bayer’s settlement proposal, have exposed the flaws and shortcomings of the company’s legal strategy,” Fears Nachawati co-founder Majed Nachawati said.

“There are more than 50,000 cases nationwide that remain unresolved and would remain so if this company had its way,” Mr. Nachawati continued. “This latest move is a transparently obvious attempt for Monsanto to subvert Judge Chhabria’s denial of the future class.”

The Dallas-based Fears Nachawati Law Firm represents individuals in mass-tort litigation, businesses and governmental entities in contingent litigation, and individual victims in complex personal injury litigation. The largest and most diverse products liability law firm in the nation, Fears Nachawati was ranked number one nationally in products liability filings in federal court over the past three years. For more information, visit https://www.fnlawfirm.com.   

Robert Tharp
Fears Nachawati Law Firm
+1 214-559-4630
email us here


Source: EIN Presswire

Substrata announces Bacto-Zyme for sale

The enzyme based product is used for odor elimination and degreasing

Bacto-Zyme helps us reach our sustainability goals with its zero harmful residues and working with the Substrata team is easy.”

— Rhiannon Woo

HENDERSON, NEVADA, UNITED STATES, July 30, 2021 /EINPresswire.com/ — Henderson, Nevada based chemical manufacturing company Substrata announced today their enzymatic microbial cleaner Bacto-Zyme is available for purchase by formulators.

Bacto-Zyme is an enzyme-based odor eliminator and degreaser. Instead of masking odors the enzymes eat odors, permanently removing them. Bacto-Zyme is 100% environmentally friendly. It has been proven safe for waste dumps, landfills, and misting systems used in livestock farming.

When used as a degreasing agent Bacto-Zyme’s enzymes reduce the surface tension of grease allowing it to be easily lifted off by either spraying or wiping. It’s been used for mold remediation and has been successfully used in hydroponic gardening systems to remove biofilm, significantly saving on time.

“Bacto-Zyme helps us reach our sustainability goals with its zero harmful residues and working with the Substrata team is easy,” said Rhiannon Woo of OnePointOne, a vertical farming company.

Regular use of Bacto-Zyme will keep grease traps, drains, garbage disposals, wet wells and septic systems free flowing and odorless.

There is no special procedure to using Bacto-Zyme, just dilute it with water.

To learn more about the different uses of Bacto-Zyme you can visit bacto-zyme.us.

About Substrata

Substrata has quickly become the go-to bio-chemical manufacturer of enzyme-based products, serving government agencies, commercial businesses and farmers worldwide. Products created by Substrata are natural enzyme-based compounds that are ideal for road and soil stabilization, soil conditioning, petroleum bioremediation, cleaning and odor control. To learn more about Substrata products, call 702.825.2500 or visit www.substrata.us.

Alfonso Martinez
Substrata
+1 702-825-5200
amartinez@substrata.us


Source: EIN Presswire

Quantum Farma y FarmaUSA lanzan cannabinoides enfocados en el tratamiento del cáncer y el dolor crónico en Brasil

Quantum Farma Logo

Quantum Farma Logo

Farma USA logo

Referencias en el segmento de Cannabis Medicinal, las empresas se unen para ofrecer productos que elevan la efectividad de cuidados paliativos a nuevos niveles

SAO PAULO, BRAZIL, July 30, 2021 /EINPresswire.com/ — Quantum Farma, una empresa con sede en el Reino Unido que ofrece altos productos y servicios que contienen cannabinoides de grado para pacientes en América Latina y otros regiones, en alianza estratégica con FarmaUSA, empresa especializada en la fabricación e importación de medicamentos y pionero en cannabinoides medicinales en Brasil, prometen un hito en el mercado de farmacias de Brasil.

Juntos, el 28 de julio, lanzaron dos medicamentos innovadores en un evento exclusivo en línea para más de 600 médicos: Medrosan Forte, que tiene una alta concentración de THC, y Medrosan Extra, que incluye cannabigerol, un nuevo tipo de cannabinoide cuya prescripción va en aumento Mundial.
Producidos orgánicamente, MEDROSAN Forte y MEDROSAN Extra se originan a partir de semillas genéticas, desarrolladas por la empresa suiza Medropharm y auditadas por el Swiss Medicines Agency, desde la semilla hasta la botella.

MEDROSAN Forte combina cannabidiol (CBD) (75 mg / ml) y tetrahidrocannabinol (THC)
(9mg / ml), cannabinoides con muy alto potencial terapéutico (CBD: THC 8: 1). Es una de las dosis más altas de THC en un producto de cannabis de espectro completo en Brasil, producido íntegramente en el área farmacéutica en Suiza. Los estudios en todo el mundo han demostrado la potencial de tal producto como adyuvante en el tratamiento de síntomas relacionados con quimioterapia, que contribuye al alivio del dolor, las náuseas y la pérdida del apetito, así como en síntomas en fibromialgia y cuidados paliativos.

MEDROSAN Extra, por su parte, presenta Cannabigerol (CBG) (50mg / ml) + Cannabidiol
(CBD) (12,5 mg / ml) (CBG: CBD 4: 1). Es un producto de cannabis medicinal que, aunque no contiene THC, es Full Spectrum ya que proviene de una planta con genética pura, que produce indetectables cantidades de THC y contiene CANNABIGEROL, el cannabinoide que está ganando mercado rápidamente compartir y popularidad dentro de la comunidad científica. Su formulación combina CBG y CBD, en sinergia, además de estar libre de THC. Entre las posibles aplicaciones se encuentran: anti- inflamatorio (en este sentido, mucho más potente que el cannabidiol) y potente músculo relajante, además de ser ideal para personas que no pueden consumir THC.

“Quantum Farma esta comprometido con la distribución de medicamentos GMP (del inglés Good Manufacturing Practices) suizos de alta calidad a América Latina. Estamos emocionados de contribuir al acceso de Medrosan Forte y Extra en todas las regiones de Brasil ”, dice Karan S. Madan, director ejecutivo de Quantum Farma.

“Estos lanzamientos refuerzan la misión de FarmaUSA, que es brindar servicios exclusivos, innovadores y Tratamientos de renombre mundial para el territorio nacional, contribuyendo a una mejor calidad de vida para los pacientes, y ofreciendo todo el apoyo de información y conocimiento para que los médicos se sientan seguros en sus recetas ”, dice Helder Dário Colmenero, Director Técnico de FarmaUSA.

—————————————————-
Sobre Quantum Farma

Quantum Farma es una empresa sanitaria global que actúa como agente de distribución de
productos farmacéuticos que contienen cannabinoides y brinda servicios a pacientes en Latinoamérica y otras regiones. La empresa atiende a una amplia variedad de pacientes y consumidores ofreciendo productos y servicios de primera calidad donde más se necesitan.

Sobre FarmaUSA
FarmaUSA es una empresa farmacéutica fundada en 2005 en EE. UU. Y ha estado operando en Brasil desde 2013, convirtiéndose en el primero en Cannabis Medicinal, con el propósito de brindar acceso humanizado a tratamientos exclusivos para miles de pacientes, con innovadores y medicamentos de renombre, como Purodiol, Isodiolex y Nabix.
FarmaUSA promueve, con un enfoque ético, información relevante para miles de médicos en todo Brasil y tiene un fuerte compromiso con todas las familias.

Sobre Medopharm
Medropharm GmbH se especializa en la extracción, producción y comercialización de productos farmacéuticos. productos de calidad y que contienen cannabinoides que contribuyen activamente a la preservación de salud y calidad de vida. Todo bajo la certificación de la Agencia Suiza de Medicamentos.

Agostina Obeid
Quantum Farma
info@quantumvent.com


Source: EIN Presswire

Inoue Perfumery MFG joins BuyChemJapan

Inoue has entered into a product promotion partnership with BuyChemJapan Corporation

Inoue has entered into a promotional partnership with BuyChemJapan Corporation and its online chemical marketplace to promote 100+ of their aroma chemicals

OSAKA CITY, OSAKA PREFECTURE, JAPAN, July 30, 2021 /EINPresswire.com/ — BuyChemJapan Corporation (President: Masa Oguchi) is pleased to announce that Inoue Perfumery MFG (President: Hiroyuki Inoue) has joined the growing number of Japanese chemical manufacturers who have decided to join the roster of companies who will sell their products via the upcoming online chemical marketplace BuyChemJapan.

Inoue Perfumery MFG Co., Ltd was established in 1950 as a manufacturer of high-quality perfumes and has since expanded its business into the fields of fragrance and fine chemicals. By developing itself into a one-stop service, doing everything from research to manufacturing to distribution, Inoue has established its reputation as a world-class Japanese brand that handles over 2,000 types of single fragrances. Under this new agreement, chemical buyers around the world can connect with Inoue and its products through the BuyChemJapan Corporation-operated BuyChemJapan marketplace.

BuyChemJapan Corporation is a start-up spun off from Daishin Corporation, a trading company specializing in chemicals. With a deep understanding of the needs and business practices of both domestic and foreign manufacturers and buyers within the chemical industry, BuyChemJapan Corporation can actively promote Japanese competitive chemicals to overseas buyers through its upcoming free online marketplace, which will specialize in introducing chemical products and promoting brand recognition. In a marketplace shaped by the COVID-19 pandemic, companies can no longer carry out traditional sales activities, so the time to shift to digital, online activities has come.

BuyChemJapan marketplace has been designed from the ground up to help simplify the process of introducing the demands of buyers to leading Japanese chemical manufacturers. Buyers can…

Search for the required chemical via a comprehensive set of options and definitions.
Make direct contact with the manufacturer with one click, removing the need to deal with intermediaries.
Request a sample, price quotation or make an order directly from the manufacturer.
Make a fully informed purchasing decision through use of a function which allows for direct comparison of chemical qualities and manufacturers costs (available post launch).
Buy with complete confidence as the marketplace is only partnered with manufacturers who produce chemicals at their own factories.
Any business currently being undertaken can be re-routed through BuyChemJapan, benefiting from the additional transparency and convenience the service provides.

BuyChemJapan Corporation is actively searching for and partnering with a rising number of chemical manufacturers and will launch its marketplace in September 2021 to optimize transactions for both manufacturers and buyers. Watch this space!

If you are an international chemical buyer who wants to negotiate directly with Japanese chemical manufacturers rather than go through troublesome, and expensive, intermediaries, then this is the service for you! Those wishing to be notified of the launch of BuyChemJapan Corporation’s new marketplace can click here and sign up for notification of when the marketplace launches.

Online Marketplace buychemjapan.com (Online early September 2021)
Corporate Website https://en.buychemjapan.co.jp/
Company Email marketing@buychemjapan.com
Telephone 81-6-6371-3730
Youtube https://www.youtube.com/channel/UCZQJLAxokdnl1SSNvievzSQ
Twitter https://twitter.com/buychemjapan
Facebook https://www.facebook.com/BuyChemJapan
LinkedIn https://www.linkedin.com/company/buychemjapan

Yousuke Nishida
BuyChemJapan Corporation
+81 6-6371-3730
email us here


Source: EIN Presswire

Quantum Farma and FarmaUSA launch cannabinoids focusing on cancer and chronic pain treatment in Brazil

Quantum Farma Logo

Quantum Farma Logo

Farma USA logo

References in the Medicinal Cannabis segment, the companies come together to offer products that raise the effectiveness of palliative care to new levels.

SAO PAULO, BRAZIL, July 30, 2021 /EINPresswire.com/ — Quantum Farma, a UK based company that provides high grade cannabinoid containing products and services to patients in Latin America and other regions, in a strategic partnership with FarmaUSA, a company specializing in the manufacture and import of medicines and a pioneer in Medicinal Cannabinoids in Brazil, promise a milestone in the Brazil's pharmacy market.

Together, on July 28, they launched two innovative drugs at an exclusive online event for more than 600 doctors: Medrosan Forte, which has a high concentration of THC, and Medrosan Extra, which includes cannabigerol, a new type of cannabinoid whose prescription is growing worldwide.
Organically produced, MEDROSAN Forte and MEDROSAN Extra are originated from pure genetic seeds, developed by Swiss company Medropharm and audited by the Swiss Medicines Agency, from the seed to the bottle.

MEDROSAN Forte combines Cannabidiol (CBD) (75mg/ml) and Tetrahydrocannabinol (THC) (9mg/ml), cannabinoids with very high therapeutic potential (CBD:THC 8:1). It is one of the highest dosages of THC in a Full Spectrum cannabis product in Brazil, entirely produced in the pharmaceutical area in Switzerland. Studies around the world have demonstrated the potential of such a product as an adjuvant in the treatment of symptoms related to chemotherapy, contributing to the relief of pain, nausea and loss of appetite, as well as in symptoms in fibromyalgia and palliative care.

MEDROSAN Extra, on the other hand, presents Cannabigerol (CBG) (50mg/ml) + Cannabidiol (CBD) (12.5mg/ml) (CBG:CBD 4:1). It is a medicinal cannabis product that, although THC-free, is Full Spectrum as it comes from a plant with pure genetics, which produces undetectable amounts of THC and contains CANNABIGEROL, the cannabinoid that is fast gaining market share and popularity within the scientific community. Its formulation combines CBG and CBD, in synergy, in addition to being THC-free. Among the possible applications are: anti-inflammatory (in this respect, much more powerful than cannabidiol) and powerful muscle relaxant, in addition to being ideal for people who cannot use THC.

“Quantum Farma is committed to bringing high quality Swiss GMP medicines to Latin America. We are excited to contribute to the access of Medrosan Forte and Extra in all regions of Brazil”, says Karan S. Madan, CEO of Quantum Farma.

"These releases reinforce FarmaUSA's mission, which is to provide exclusive, innovative and world-renowned treatments for the national territory, contributing to a better quality of life for patients and offering all the support of information and knowledge so that doctors feel safe in their prescriptions”, says Helder Dário Colmenero, Technical Director of FarmaUSA.
—————————————————-
About Quantum Farma
Quantum Farma is a global healthcare company that acts as a distribution agent for pharmaceutical products containing cannabinoids and provides services to patients in Latin America and other regions. The company serves a broad cross-section of patients and consumers by delivering premium quality products and services where they are needed most.
About FarmaUSA

FarmaUSA is a pharmaceutical company founded in 2005 in the USA and has been operating in Brazil since 2013, becoming the first in Medicinal Cannabis, with the purpose of providing humanized access to exclusive treatments for thousands of patients, with innovative and renowned medicines, such as Purodiol, Isodiolex and Nabix. FarmaUSA promotes, with an ethical approach, relevant information to thousands of physicians throughout Brazil and has a strong commitment to all families.

About Medopharm
Medropharm GmbH specializes in the extraction, production and marketing of pharmaceutical-grade and cannabinoid-containing products that actively contribute to the preservation of health and quality of life. All under Swiss Medicines Agency certification.

Agostina Obeid
Quantum Farma
agostina@quantumvent.com


Source: EIN Presswire

Australian Nanoshield Antiviral Product Effective Against SARS-CoV-2

Nestlé Research sets real world evaluation benchmark for commercially available antiviral coatings. Results confirm only Nanoshield met all criteria

In the current COVID environment a lot of claims are being made about the efficacy of commercially available antiviral products without solid scientific evidence,.”

— Alfred Chong, Executive Chairman and CEO of Nannoveu.

PERTH, WESTERN AUSTRALIA, AUSTRALIA, July 30, 2021 /EINPresswire.com/ — Every day Australians going about their normal lives touch surfaces that are potential virus carriers. From banks to airports, from office buildings to public transport the potential to pick up bacteria and viruses, including the SARS-CoV-2 virus that causes COVID-19 could be lurking.

There are any number of commercially available antiviral sprays and films claiming to provide surface protection for communities that to date have been untested, especially not in a normal working environment. In fact, as a COVID-19 precaution, many businesses have shut down access to commonly used terminals and screens to protect people against surface transmission of the virus. That has now changed.

For the first time peer reviewed scientific research on a selection of readily available antiviral surface protection products has been carried out to test their claims in an every- day, real world environment.
Clinical testing carried out by researchers from Nestlé Research’s, Institute of Food Safety and Analytical Science, in Lausanne, Switzerland on a number of protection products has now been published in Applied and Environmental Microbiology the journal of the American Society of Microbiology. It showed that the antiviral surface protection film Nanoshield, developed by Australian nanotechnology company Nanoveu Ltd is highly effective in providing surface protection against SARS-COV-2, the virus that causes COVID-19.

The research concluded Nanoshield was the most effective at reducing SARS-CoV-2 (COVID-19) immediately, in durability testing and also effective despite the presence of other organic matter.

The research identified that while SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is transmitted mainly by person-to-person through respiratory droplets, antiviral coating solutions offer an additional measure to mitigate the risk of SARS-CoV-2 transmission from high-touch surfaces.

“The deployment of antiviral coatings is not new, but what is currently lacking is solid scientific evidence of the efficacy of commercially available self-disinfecting surfaces under real-life conditions,” the Nestle report stated.

“A novel and robust approach to evaluate the antiviral activity of coatings was developed, assessing three commercially available leave-on surface coating products for efficacy against human coronaviruses HCoV-229E and SARS-CoV-2. The assessment is based on three criteria that reflect real-life settings, namely (i) immediate antiviral effect, (ii) effect after repeated cleaning of the coated surface, and (iii) antiviral activity in the presence of organic material. The results showed that only a copper compound-based coating successfully met all three criteria.”

The Nestle research identified that this new approach now creates a benchmark upon which all currently available antiviral coatings and future coating developments should be judged to avoid unjustified claims.
“In the current COVID environment a lot of claims are being made about the efficacy of commercially available antiviral products without solid scientific evidence,” said Nannoveu executive chairman and CEO, Alfred Chong. “The Nestlé results confirm Nanoshield’s status as a globally significant product with the ability to make surfaces safer.”

“We have long believed the importance of scientific research in the efficacy of our products, and we welcome the validation of our claims as the leading antiviral coatings for high touch surfaces,” Mr Chong said. “Many businesses and government agencies have been looking to science to address the challenges of ‘living with COVID’ as the pandemic rages through countries. This is now one solution!

“Now the scientific research has been reviewed and published, Nanoshield becomes one of the most economical options to deliver protection and peace of mind.”

Report Summary
Citing the lack of solid scientific evidence surrounding commercially available self-disinfecting surface coatings under conditions that mimic real-world use, Nestlé Research analysed the effectiveness of Nanoshieldt and two other products under a number of conditions, for immediate anti-viral activity, longer-term durability after repeated cleaning of the coated surface and the anti-viral activity after frequent touching by human hands.

Base-case test conditions saw the three commercially available products assessed against SARS-CoV-2 and human coronavirus HCoV-229E. Short evaluation periods were chosen to reflect real-world use cases where anti-viral activity needs to occur within a rapid timeframe.

Initial testing was conducted using the HCoV-299E virus; another human coronavirus and a recognised surrogate for SARS-CoV-2. Of the three products, at time stamp ‘0’ one showed no reduction of the HCoV-229E virus, 30 minutes and no antiviral activity at 120 minutes. Based on these results it was not investigated any further.
Of the other two products, at time stamp ‘0’ Nanoshield inactivated a higher percentage of HCoV-229E of the two (approx. 99.95% vs 99%). As both products showed immediate anti-viral activity against the surrogate, evaluation using the SARS-CoV-2 virus (COVID-19) after 0, 30 and 120 minutes was conducted at room temperature. Nanoshield achieved approx. 99.99% compared to 96%.

Simulated real-world cleaning procedures of the coated surfaces was also done using microfiber cloths and both a water-based detergent and 70 percent ethanol. The coatings were wiped with both solutions 1, 7, 30 and 90 times. The antiviral activity of Nanoshield remained intact after 90 wipes with a microfiber cloth using both water-based detergent and alcohol sanitiser. The antiviral activity of the other product was completely removed after one round of cleaning with either cleaning product.

As Nanoshield successfully passed the first two research criteria it was further evaluated for the touch criteria. The film was touched between 10 to 50 times by unwashed hands prior to virus inoculation to simulate the daily use of a high touch surface.

Fifty touches correspond to a daily touching frequency of a highly used vending machine. Once clean of organic matter, Nanoshield’s full efficacy was reinstated, suggesting a daily clean is sufficient. As Nanoshield fulfilled all three evaluation criteria it can be considered an efficient antiviral coating.

Based on the outcomes of the scientific review, Nestle Research deemed Nanoshield the preferred antiviral coating solution.

Further information: https://journals.asm.org/doi/10.1128/AEM.01098-21

Phil Burfurd
Daylight Agency
+61 414 260 292
pburfurd@daylightagency.com.au


Source: EIN Presswire

STP and STC announce the release of its newly developed EHS audit protocol for New South Wales, Australia

Latest EHS Regulations Updates Assist Companies to Achieve EHS Compliance

VANCOUVER, BRITISH COLUMBIA, CANADA, July 29, 2021 /EINPresswire.com/ — STP ComplianceEHS (STP) and Specialty Technical Consultants (STC) announce the release of its recently updated EHS protocol for New South Wales, Australia. This audit protocol, which covers relevant national and State of New South Wales EHS requirements, was previously updated in March 2019. The regulatory date for the current release is March 2021.

Leading companies around the world use EHS audit protocols to understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, and export audit findings in a cost-effective manner. EHS audit protocols are prepared by STC in partnership with STP and continue to focus on those national (plus, in some cases, regional or provincial) EHS requirements that have site-specific applications for manufacturing operations. As a leading EHS management consulting firm with a global network of experienced EHS teaming partners, STC has in-depth knowledge and technical expertise of local/regional EHS requirements.

STP and STC maintain leading-edge EHS audit protocols for more than 50 jurisdictions. The protocol documents are written in English and are available in MS Word, Adobe Acrobat and Excel formats, as well as through STP’s web-based portal or can be integrated into an existing company platform. Using the protocols’ custom templates and advanced functionality features, auditors can easily track audit findings and manage data over time to improve compliance, risk management and safety performance. In addition, STP’s formatting is compatible with leading risk management and sustainability platform providers.

Highlights of selected legislation covered in the newly developed protocol include:

The national Ozone Protection and Synthetic Greenhouse Gas Management Regulations 1995 were updated to incorporate new rules for charging refrigeration and air conditioning equipment which came into force on 1 January 2020 to support the hydrofluorocarbon (HFC) phase-down and reduce emissions of climate-damaging HFCs. These Rules ban the charging of refrigeration and air conditioning equipment with a higher global warming potential (GWP) refrigerant than the equipment was designed to use, with an exception for refrigeration or air conditioning equipment that is essential for health or public safety purposes where the design refrigerant is not available.

The national Product Emissions Standards Rules 2017 were updated to delay the commencement of the prohibition on supplying an emissions-controlled product that was due to commence on 1 July 2019 for 12 months, until 1 July 2020. The delay will allow an additional 12 months for suppliers and retailers to sell uncertified stock that was imported before the commencement of the import prohibition. Under the Product Emissions Standard Rules, certain propulsion marine engines and non-road engines are designated as “emissions-controlled products” which must be certified as meeting the Australian emissions standard, or a recognized foreign standard, in order to be imported or supplied in Australia.

The National Industrial Chemicals (Notification and Assessment) Act 1989 and the Industrial Chemicals (Notification and Assessment) Regulations 1990 were repealed and have been replaced by a new regulatory scheme for industrial chemicals under the Industrial Chemicals Act 2019 and the Industrial Chemicals (General) Rules 2019.

The National Industrial Chemicals Act 2019 (assented to in March 2019) establishes a new regulatory scheme, the Australian Industrial Chemicals Introduction Scheme (AICIS), for the importation and manufacture (introduction) of industrial chemicals in Australia. The AICIS replaced the National Industrial Chemicals Notification and Assessment Scheme (NICNAS) on 1 July 2020. The AICIS establishes a new way of categorizing and introducing industrial chemicals that focuses the pre-introduction assessment on higher-risk chemical introductions and provides streamlined introduction pathways for lower-risk chemicals that are intended to reduce the regulatory burden for industry. It also focuses on post-introduction evaluation and monitoring to help maintain the protection of the health and safety of the public, workers, and the environment.

The National Industrial Chemicals (General) Rules 2019 (effective 1 July 2020) support the new industrial chemicals regulatory scheme established by the Industrial Chemicals Act 2019. These Rules set forth the technical and operational details and the requirements introducers must meet, including the requirement to categorize their chemicals that are not listed on the Australian Inventory of Industrial Chemicals.

For more information on this release click here.

For more information on all International EHS audit protocols offered by STP click here.

About STP ComplianceEHS
STP ComplianceEHS (STP) produces technical resource guides covering environmental, health & safety, transportation, business practices, standards, and law, offering comprehensive guidance on key compliance and regulatory issues. STP is a division of Glacier Media Inc., a Canadian information communications company that provides primary and essential information in print, electronic and online media. Glacier’s Business and Professional Information Group publishes directories, technical manuals, research and development materials, medical education, electronic databases, investment information, and specialty websites.

About Specialty Technical Consultants
Specialty Technical Consultants, Inc. (STC) is a specialized management consulting firm working to enhance environmental health and safety (EHS) performance. Through its consulting services, STC partners with clients to strengthen management systems' design and implementation and identifies needs and implements solutions to meet business objectives. Services provided include EHS compliance support; risk assessment; EHS auditing; corporate responsibility and sustainability; EHS management systems development and implementation; EHS regulatory information tools; and EHS training.

STC is certified as a Woman-Owned Business Enterprise (WBE) by the Women’s Business Enterprise National Council (WBENC) and the Supplier Clearinghouse for the California Public Utilities Commission, and as a Disadvantaged Business Enterprise (DBE) by the California Department of Transportation (Caltrans) Disadvantaged Business Enterprise (DBE) Program.

Natalie Elster
STP ComplianceEHS
+1 604-983-3434
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Meet CellCore’s Lead Scientist

CellCore Lead Scientist, Tim Griswold

CellCore Biosciences, Meridian, ID

Tim Griswold Is Known for His Bowtie, Dance Moves, and Scientific Innovation

MERIDIAN, IDAHO, UNITED STATES, July 29, 2021 /EINPresswire.com/ — CellCore Biosciences, Meridian-based health company, is known for its life-changing supplements and innovative laboratory team. That team of health solution masterminds is led by lead scientist, Tim Griswold. Tim’s personal health struggles were what originally led him to the field of naturopathics science.

Tim shares, “During my undergrad years, I started having some internal medical concerns and set about on a journey to try and discover the cause and possible solutions. I determined that in order for me to heal, I would need to get to the root cause. This led me to my master’s work where I got to study atomic particle movement and the quantum nature of the universe.”

The scientist has his Master of Nanoscience from Arizona State University, where he focused on learning the physics of biology and chemistry at the ultra small scale. Prior to that he earned two bachelor’s degrees from the University of Idaho in chemical engineering and chemistry.

Tim is also a family man. Married for three years, he and his wife, Carolyn, just had their first child, Ezekiel, in late May. Along with Tim’s intelligence, his fun-loving personality is demonstrated in his iconic bowtie and eye-catching dance moves. Tim says, “I like to show people that I am more than just an analytical, science brain, so I do my best to surprise people and have fun! And dancing, well dancing is the soul saying hello… which makes everything more fun.”

At CellCore’s biannual practitioner event, ECO, Tim is a highly regarded speaker. In April 2021 at ECO Orlando, Tim presented on Carbon Technology and on atomic states. During the breaks, Tim told a few science jokes and let his “soul say hello” with some dancing.

Tim says, “CellCore Biosciences is a fantastic company to be a part of. Its goals, mission, company culture, and new frontiers all get me excited to put my pants on and come to work everyday. This role as lead scientist has allowed me to dedicate my expertise in nanoscience to something that matters.”

Tim’s thorough understanding of everything that defines chemistry has been instrumental in advancing CellCore’s proprietary Carbon Technology.

Tim says, “This role of lead scientist has given me the opportunity to incorporate my knowledge of ultra small particles into the realm of physiology. This fundamental understanding has helped our team develop technologies that store and produce energy within natural carbon-based molecules. These molecules can be introduced as an aid in health and healing that supplies energy, but also supplies the raw carbon backbone materials used to build and restore tissue.”

He continues, “The success stories make it all worthwhile, where people go from a low energy, low excitement, unwell state and then their countenances slowly start to change as we assist them in their health journey. My condition has greatly improved by using this unique technology, and I am excited to share it with the world.”

About CellCore Biosciences: CellCore Biosciences is a wellness company that believes a “healthy microbiome is a healthy you.” This starts with opening drainage pathways, supporting energy at the mitochondrial level, and detoxing unwanted substances. Their core values are front and center in the company mission: “Creating solutions that work is what we do. Restoring hope and health is who we are.”

If you would like more information about this topic, please contact Jessica Tidwell, Public Relations Manager for CellCore Biosciences, at jessica.tidwell@cellcore.com.

Jessica Tidwell
CellCore Biosciences
email us here


Source: EIN Presswire

Tx3 Listed as Sample Vendor in 2021 Gartner Hype Cycle for Life Science Manufacturing, Quality and Supply Chain Report

Tx3 Services Logo

Tx3 Services

Tx3 Services was recognized among 9 vendors in the Digital Validation Tools Category

DOYLESTOWN, PA, UNITED STATES, July 29, 2021 /EINPresswire.com/ — Tx3 Services, a leading solution provider of FDA compliance solutions in software quality and software testing, today announced that it has been identified as a Sample Vendor in the 2021 Gartner ® Hype Cycle™ for Life Sciences Manufacturing, Quality and Supply Chain report. Tx3 Services was named in the Digital Validation category. [1]

Although a highly impactful and high yield methodology, Digital Validation is still somewhat of an emerging practice for many Life Sciences organizations. However, it has become increasingly important as more and more teams are remote and geographically dispersed.

Further, with business units requiring higher quality at faster speed, along with continued cloud and digital transformation initiatives, traditional approaches to validation have become less practical and more disruptive than ever. As a result, more organizations are beginning to adopt approaches to validation that are less reliant on traditional documentation, and instead leverage a more embedded, automated, and digital approach to computer systems validation to meet their software quality and compliance objectives.

According to the report, “Gartner has observed renewed interest from manufacturers on how digital and virtual validation will transform existing best practices as companies seek to transition to paperless and more automated operations.” [1]

As a practice that Tx3 has been promoting for years, digital validation seems to be taking a stronghold amongst forward-thinking Life Science organizations. We believe that the continued research provided by such a venerable market analysis source as Gartner should only help to encourage teams to evaluate its merits.

"Our primary focus as an organization has been to develop a robust digital validation platform that enables a more nimble, modern approach to validation and testing regulated applications for our clients," said Eric Toburen, Managing Partner at Tx3 Services. "We consider that being named by Gartner as a Sample Vendor just helps to reinforce our solution’s place in the Life Sciences world."

[1] Gartner, “Hype Cycle for Life Science Manufacturing, Quality and Supply Chain, 2021”, Michael Shanler, Andrew Stevens, Rick Foranzosa, 20 July 2021.
Gartner Disclaimer:

GARTNER and Hype Cycle are a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission.

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose

Jason Secola
Tx3 Services
+1 877-225-6677
email us here


Source: EIN Presswire

rfxcel to Work with Hypera Pharma to Ensure Compliance with SNCM Traceability Requirements

rfxcel with AVG payoff

RENO, NEVADA, UNITED STATES, July 29, 2021 /EINPresswire.com/ — rfxcel, part of Antares Vision Group and a global leader in digital supply chain traceability solutions, today announced it had signed a contract with Hypera Pharma, the largest pharmaceutical company in Brazil, to ensure it complies with traceability requirements in the country’s National System for the Control of Medicines (SNCM).

Hypera Pharma’s objective is to adapt its internal processes to the SNCM, due to take full effect in 2022 but whose first adjustments came into force at the end of 2020. The company owns a several brands in the over-the-counter medications segment, including Maracujina, Benegrip, Engov, and Epocler, and expects sales of R$5.9 billion in 2021.

rfxcel’s technology will help Hypera Pharma trace drugs in its supply chain, control internal systems integrations and external connections with business partners, and help to generate compliance reports for regulatory bodies, including the Brazil National Health Surveillance Agency (ANVISA).

The compliance reports will contain all information about every drug transaction and their path along the supply chain, from the factory to the final destination at retail pharmacies and hospitals.

Founded in 2003, rfxcel has implemented 1,000 similar traceability solutions for more than 250 customers in the pharmaceutical, food and beverage, and consumer goods industries. It expanded to the Brazilian market in 2018.

In May 2021, the company was bought by Antares Vision Group, a leading global provider of intelligent track and trace, inspection, and smart data management solutions for the life sciences and food and beverage sectors.

For more information about rfxcel’s traceability solutions, contact Vice President of Marketing and Strategic Initiatives Herb Wong at hwong@rfxcel.com and visit rfxcel.com, or Antares Vision PR Specialist Davide Antonioli at davide.antonioli@antaresvision.com and visit AntaresVision.com.

About rfxcel
rfxcel, part of Antares Vision Group, provides leading-edge software solutions to help companies build and manage their digital supply chain, lower costs, and protect their products and brand reputations. Blue-chip organizations in the life sciences (pharmaceuticals and medical devices), food and beverage, worldwide government, and consumer goods industries trust rfxcel’s signature Traceability System (rTS) to power end-to-end supply chain solutions in key areas such as track and trace, environmental monitoring, regulatory compliance, serialization, and visibility. Founded in 2003, the company is headquartered in the United States and has offices in the United Kingdom, the EU, Latin America, Russia, India, Japan, the Middle East, and the Asia-Pacific region.

About Antares Vision Group
Listed since April 2019 on the Italian Stock Exchange in the AIM Market, and from 14 May 2021 on Mercato Telematico Azionario (MTA) STAR segment, the Antares Vision Group guarantees protection of products, people and brands through inspection systems for quality control, Track & Trace solutions for anti-counterfeiting and supply chain transparency, smart data management tools for maximized efficiency and digitalization of the supply chain, from raw materials to the final consumer. The Antares Vision Group is active in the pharmaceutical market and in Life Science in general (biomedical devices and hospitals), in beverage, food, cosmetic and in consumer-packaged goods. The Group reaches over 60 countries in the World with complete and flexible solutions, hardware, and software, with related services and counts 7 production facilities in Italy (Brescia, Parma, Piacenza, Latina, Padua and Vicenza), 22 foreign subsidiaries (Germany [2], France [2], USA [5], Brazil [2], United Kingdom [2], India, Russia [3], Hong Kong, China, Ireland, Croatia and Serbia), 3 Innovation and Research Centers (Italy) and a worldwide network of more than 40 partners. Thanks to the twenty years of experience in vision technologies of the two founding partners, the Antares Vision Group is the supplier of 10 out of 20 leading pharmaceutical companies in the world, with more than 25.000 inspection systems, that ensure everyday product safety and quality, 6.500 quality controls and more than 3.500 serialization modules on lines installed all over the. With the aim of continuing and supporting the growth and development strategy, during 2019 participation agreements were finalized with T2 Software, a Brazilian company specialized in smart data management solutions, and Orobix, an Italian company leader in artificial intelligence services, as well as the acquisition of 100% of FT System, leader in control and inspection in the beverage sector. In 2020, Antares Vision acquired 82.83% of Tradeticity, a Croatian company specialized in software management of traceability and serialization processes, 100% of Convel, an Italian company specialized in automated inspection machines for the pharmaceutical industry, the assets of Adents High Tech International, a French company specialized in software for serialization and traceability, 100% of Applied Vision, a global leader in inspection systems for glass and metal containers in food beverage. In March 2021, Antares Vision acquired 100% of rfxcel Corporation, specialized in software solutions for digitalization and supply chain transparency based in the U.S., and 100% of Pen-Tec and Tecnel, through FT System, increasing specialization in Food & Beverage inspection sector. In 2019 Emidio Zorzella and Massimo Bonardi won the Ernst & Young “Entrepreneur of the Year” award for innovation.

Herb Wong
rfxcel Corporation
+1 925-824-0300
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

rfxcel: A Leader in Patient Safety through Traceability


Source: EIN Presswire